Dear Colleagues,
We stand at the start of a brand new year, posing new opportunities and hope for the future.
Last year was an important time period for us we together made progress on several important fronts.
Jubilant Therapeutics, an innovation focused biotech working on proprietary novel drugs under Jubilant Pharmova successfully transformed to clinical stage with its first in-house discovered oral oncology pipeline drug (Dual LSD1/HDAC6 inhibitor) starting Phase I clinical trial and receiving orphan drug designation from FDA. The year saw us achieving successful FDA clearance of IND filing for our second oncology pipeline drug (PRMT5 inhibitor), that is now ready for Phase I trial. The Company was invited to present its R&D at leading global conferences such as AACR (American Association of Cancer Research).
None of our achievements would have been possible without the collaborative efforts of our team. I thank each and every team member for their untiring efforts and commitment towards the goals of the organisation. In the new year 2023, we look forward to making further development progress in our pipeline drugs and entering into partnerships with big pharma/ investors.
Here’s wishing the global Jubilant family a very Happy New year!
Regards
Dr. Syed Kazmi - President & CEO,
Jubilant Therapeutics Inc.